of treatment. We suggest that more attention should be directed to evaluating new or old anticonvulsants in newly diagnosed untreated patients.
Finally, our results may have been influenced by the relative lack of associated neuropsychiatric handicaps (table I) , which have been shown to be associated with a generally poorer prognosis."1 On the other hand, although we excluded patients with obviously progressive neurological diseases, our patients are typical of those referred to a neurological clinic and representative of most adult epileptic patients. Further studies of this type should certainly be undertaken in a more brain-damaged population and also in children, in whom epilepsy is so common.
Whether those patients who continue to have seizures despite an optimum blood concentration of one drug will be improved by the addition of another drug is still uncertain. We have not observed any further improvement in the few patients who failed on a single drug but the numbers were too small to draw firm conclusions. In our retrospective study of chronic patients,6 however, the addition of a second drug was not usually associated with improved control, but when control did improve it was usually associated with an optimum blood level of one of the drugs. It is at least possible, therefore, that polypharmacy is totally unnecessary and we may have to adjust to the idea that some patients will continue to have attacks with one drug instead of continuing to have them, as is usually the case, with multiple drugs. Only further studies will clarify this.
We conclude from our two prospective trials and retrospective study that there is now considerable potential for improving the quality and results of treatment of epileptic patients. In the population we studied polypharmacy appears to be largely unnecessary and most patients can be satisfactorily treated from the beginning with one drug, assisted by blood level monitoring.
An added advantage of this policy will be the associated reduction in chronic toxicity and economic costs. 
Introduction
The hyperviscosity syndrome is a symptom complex of neurological dysfunction, visual disturbances, and a haemorrhagic tendency caused by increased blood viscosity. It is classically associated with Waldenstrom's macroglobulinaemia, and is a more recently recognised complication of myelomatosis-in both cases the symptoms resulting from increased plasma viscosity produced by the abnormal circulating paraprotein.1 2 Generally, however, the packed cell volume is the most important factor affecting blood viscosity, and the symptoms resulting from abnormal viscosity in polycythaemia vera are well recognised. Though white blood cells on the other hand normally contribute little to whole blood viscosity, patients with leukaemia may develop the hyperviscosity syndrome as a direct consequence of a grossly raised white blood cell count. We report studies on six patients and the results of treating them with leucapheresis. 
Results of viscosity studies
The viscosity of the whole blood, but not plasma, measured at both rates of shear, was increased in all six patients. Serial measurements (fig 1) show that for a given increment in white cell count there is a significantly greater increase in whole blood viscosity in the patients with myeloid leukaemias than in those with lymphoid leukaemias. The MWCVs were 180-337 fl in the patients with lymphoid leukaemias and 731-923 fl in the patients with myeloid leukaemias. Clinical responses were excellent in three patients, satisfactory in one, and poor in two. One patient (case 3) who had been extremely lethargic and drowsy before leucapheresis was discharged symptomfree two days later. Another (case 5) could hear normal speech after treatment, whereas she had been almost stone deaf before; and a third (case 4) recovered normal gait 24 hours after leucapheresis and no longer complained of recurrent blurring of vision. There was no improvement in the auditory acuity of the fourth patient (case 5), but her gait, which had been definitely ataxic, retumed to normal two days later. Two patients died after leucapheresis. One (case 1) was comatose when treated and died shortly afterwards without recovering consciousness; although leucapheresis greatly reduced her whole blood viscosity, it did not restore it to normal. The general condition of the other patient (case 2) improved for about 18 hours after leucapheresis, but he then rapidly lost consciousness and died shortly after starting chemotherapy. Just before his death there was haematological evidence of intravascular coagulation, which was confirmed by histological examination of the brain. This complication of chemotherapy in acute leukaemia is attributed to the release of thromboplasmins from damaged blast cells. and whole blood viscosity in patients with leukaemia.
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Discussion
Although white blood cells normally make little contribution to the viscosity of the blood, it has been suggested that granulocytes have a greater effect on it than whole blood viscosity measurements indicate.4 Increased concentrations of white cells moreover may greatly influence the viscosity of packed red cells.5 Several workers have shown the high intrinsic viscosity of white blood cells,5 6 and it has been suggested that some of the clinical features of chronic granulocytic leukaemia may result from the effects on viscosity of the increased white cell mass.7 Our data suggest that this may be true of several morphological types of leukaemia.
Neurological symptoms are not uncommon in patients with leukaemia. They can be produced by leukaemic infiltration into the central nervous system and haemorrhage, and some are accentuated by the electrolyte imbalance found particularly in acute myeloblastic leukaemia and the blast crisis of chronic granulocytic leukaemia. Nevertheless, our patients showed clinical features that were identical, apart from the absence of severe haemorrhage, with those that are common in Waldenstrom's macroglobinaemia, including auditory and visual disturbances, abnormalities of gait, and alterations of consciousness. The fact that leucapheresis could rapidly abolish them is evidence that in leukaemia also these symptoms and signs may be explained solely by increased blood viscosity; and indeed the clinical responses, excellent in three cases and partial in a fourth, were associated with appreciable falls in total white blood count and whole blood viscosity.
Neurological symptoms seemed to occur at lower white cell counts in patients with myeloid leukaemias, and we found that a given increment in the white cell count of these patients produced a greater rise in blood viscosity than a similar increase in lymphocytes. Cell size is almost certainly an important factor, though probably not the only one; and the MWCVs were indeed appreciably greater in the myelogenous than the lymphoid group.
Leucapheresis is an extremely effective method for removing large numbers of circulating white cells and therefore alleviates the symptoms caused by the associated hyperviscosity. As it is not a procedure without hazard, patients should be carefully selected.
